Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:enrollment |
over 100 patients
|
| https://www.w3.org/2000/01/rdf-schema#label |
ZUMA-1 trial
|
| gptkbp:indication |
relapsed or refractory large B-cell lymphoma
|
| gptkbp:location |
gptkb:Canada
gptkb:Europe gptkb:United_States |
| gptkbp:NCT_number |
NCT02348216
|
| gptkbp:period |
Phase 1
Phase 2 |
| gptkbp:primary_endpoint |
objective response rate
|
| gptkbp:primary_investigator |
Frederick L. Locke
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:resulted_in_approval_of |
gptkb:Yescarta
|
| gptkbp:sponsor |
gptkb:Kite_Pharma
|
| gptkbp:startYear |
2015
|
| gptkbp:studiedBy |
gptkb:axicabtagene_ciloleucel
|
| gptkbp:therapy_type |
gene therapy
|
| gptkbp:bfsParent |
gptkb:Chimeric_Antigen_Receptor_T-cell_therapy
|
| gptkbp:bfsLayer |
8
|